Table 2. Meta-analysis of the correlation between NQO1 C609T polymorphism and lung cancer risk.
| Variables | No. of | Homozygous | Heterozygous | Recessive | Allele | No. of | Dominant | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| studies | TT vs. CC | CT vs. CC | TT vs. (CT+CC) | T vs. C | studies | (CT+TT) vs. CC | ||||||
| OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | |||
| All | 28 | 0.91 (0.74–1.12) | < 0.001 | 1.08 (0.96–1.21) | 0.003 | 1.13 (0.97–1.33) | 0.039 | 1.09 (0.99–1.20) | < 0.001 | 37 | 1.04 (0.94–1.16) | < 0.001 |
| Ethnicity | ||||||||||||
| Asian | 14 | 0.82 (0.62–1.09) | < 0.001 | 1.10 (0.91–1.34) | 0.001 | 1.09 (0.88–1.34) | 0.005 | 1.08 (0.93–1.26) | < 0.001 | 16 | 1.13 (0.94–1.36) | < 0.001 |
| Caucasian | 9 | 1.08 (0.77–1.51) | 0.232 | 1.08 (0.97–1.20) | 0.469 | 1.20 (0.90–1.59) | 0.422 | 1.11 (0.99–1.24) | 0.205 | 14 | 1.00 (0.89–1.13) | 0.048 |
| African | 2 | 1.22 (0.36–4.15) | 0.198 | 0.94 (0.63–1.41) | 0.880 | 1.28 (0.38–4.29) | 0.199 | 1.01 (0.73–1.41) | 0.355 | 4 | 0.93 (0.69–1.25) | 0.809 |
| Hawaiian | 1 | 1.33 (0.29–6.21) | — | 0.45 (0.23–0.88) | — | 1.67 (0.36–7.69) | — | 0.66 (0.38–1.12) | — | 1 | 0.52 (0.28–0.96) | — |
| Hispanics | 1 | 0.57 (0.14–2.37) | — | 1.21 (0.44–3.32) | 0.52 (0.14–1.95) | — | 0.84 (0.42–1.65) | — | 1 | 1.00 (0.39–2.55) | — | |
| Mixed | 1 | 2.00 (0.17–23.9) | — | 2.59 (0.82–8.18) | — | 1.63 (0.14–18.9) | — | 2.07 (0.82–5.22) | — | 1 | 2.54 (0.85–7.58) | — |
| Source of control | ||||||||||||
| PB | 13 | 1.05 (0.82–1.36) | 0.320 | 1.00 (0.87–1.15) | 0.274 | 1.16 (0.90–1.50) | 0.247 | 1.03 (0.91–1.17) | 0.043 | 19 | 0.95 (0.84–1.07) | 0.067 |
| HB | 15 | 0.85 (0.74–1.12) | < 0.001 | 1.17 (0.98–1.38) | 0.001 | 1.12 (0.91–1.38) | 0.025 | 1.14 (0.99–1.32) | < 0.001 | 17 | 1.19 (1.01–1.40) | < 0.001 |
| Quality score | ||||||||||||
| > 9 | 10 | 0.93 (0.71–1.22) | 0.186 | 1.00 (0.86–1.17) | 0.111 | 1.16 (0.81–1.67) | 0.008 | 1.02 (0.85–1.22) | < 0.001 | 14 | 0.96 (0.83–1.11) | 0.005 |
| ≤ 9 | 18 | 0.91 (0.74–1.12) | < 0.001 | 1.15 (0.98–1.36) | 0.004 | 1.10 (0.97–1.33) | 0.496 | 1.12 (1.00–1.20) | 0.001 | 23 | 1.12 (0.97–1.30) | < 0.001 |
| Smoking status | ||||||||||||
| Ever | 6 | 1.11 (0.79–1.56) | 0.113 | 1.09 (0.94–1.26) | 0.511 | 1.09 (0.78–1.53) | 0.225 | 1.08 (0.91–1.31) | 0.088 | 14 | 1.04 (0.94–1.15) | 0.283 |
| Never | 4 | 0.91 (0.48–1.74) | 0.276 | 1.11 (0.79–1.57) | 0.292 | 0.97 (0.53–1.76) | 0.396 | 1.02 (0.69–1.51) | 0.099 | 11 | 1.03 (0.82–1.28) | 0.505 |
| Lung cancer subtype | ||||||||||||
| Non-small cell | 10 | 1.34 (0.90–1.99) | 0.002 | 1.21 (0.99–1.48) | 0.031 | 1.26 (0.94–1.71) | 0.025 | 1.22 (1.00–1.48) | < 0.001 | 13 | 1.16 (0.96–1.40) | 0.001 |
| Small cell | 3 | 2.57 (1.24–5.32) | 0.730 | 1.24 (0.93–1.65) | 0.481 | 2.38 (1.16–4.88) | 0.813 | 1.35 (1.06–1.71) | 0.358 | 3 | 1.33 (1.01–1.75) | 0.388 |
Het, heterogeneity; HB, hospital based; PB, population based; NA, not available.